Cover Image
市場調查報告書

白細胞介素7受體亞單位α:開發中產品分析

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365742
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素7受體亞單位α:開發中產品分析 Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 59 Pages
簡介

本報告提供以白細胞介素7受體亞單位α為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素7受體亞單位α 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Cytheris SA
  • Genexine, Inc.
  • GlaxoSmithKline Plc
  • OSE Immunotherapeutics
  • Pfizer Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0178TDB

Summary

Global Markets Direct's, 'Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016', provides in depth analysis on Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R)
  • The report reviews Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Overview
  • Therapeutics Development
    • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Stage of Development
    • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Therapy Area
    • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Indication
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Companies
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Universities/Institutes
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Companies Involved in Therapeutics Development
    • Cytheris SA
    • Genexine, Inc.
    • GlaxoSmithKline Plc
    • OSE Immunotherapeutics
    • Pfizer Inc.
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Drug Profiles
    • Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CYT-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EFFI-7H - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GIFT-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2618960 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GX-I7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06342674 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Dormant Projects
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Discontinued Products
  • Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Featured News & Press Releases
    • Jun 12, 2013: GSK Halts Clinical Trials Of Multiple Sclerosis Drug GSK-2618960 After Fraud Claim
    • Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leucoencephalopathy
    • Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation
    • Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy
    • Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients
    • Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Nonresponders To Standard Of Care
    • Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting
    • May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions
    • May 11, 2011: Cytheris, Lyon And ImmunID Announce Initiation Of Phase IIa Combination Trial Of IL-7 And XELODA In Metastatic Breast Cancer Treatment
    • Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107
    • Dec 07, 2010: Cytheris Announces Interim Phase I Study Results Of CYT107 In Treatment Of Post-Transplant Patients
    • Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients
    • Oct 19, 2010: Cytheris Initiates ORVACS-Sponsored Phase II Clinical Study To Attack Viral Reservoir Of HIV Patients
    • Sep 23, 2010: Cytheris Initiates Phase II Clinical Trial Of CYT107 In Chronically Infected HIV Patients
    • Feb 02, 2010: Cytheris Announces Notice Of Allowance For US Patent Covering The Preparation And Uses Of Its Glycosylated Recombinant Human Interleukin-7 (CYT107)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Cytheris SA, H1 2016
  • Pipeline by Genexine, Inc., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by OSE Immunotherapeutics, H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top